Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Active treatment vs observation

Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Active treatment vs observation

Quality of life: CFRSD‐CRISS symptom score · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low

Active treatment vs observation

FEV1 % predicted: absolute change from baseline · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Very low

Active treatment vs observation

Change in weight (kg) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Active treatment vs observation

Exacerbation frequency · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Active treatment vs observation

Adverse effects of treatment · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Eradication of MRSA · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen

Oral plus nebulised antibiotics showed no clear difference in eradication of MRSA compared with oral antibiotics plus nebulised placebo (low certainty).

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
OR 1.63 [0.19, 13.93]
1 study · 25 participants
Low

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs no laser therapy

Regression of PSR: change in number and size (in clock hours or in degrees of retinal circumference) of new blood vessels · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Very low

Laser therapy vs no laser therapy

Development of new PSR: proliferation of blood vessels at a new area/progression of existing PSR after treatment · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Very low

Laser therapy vs no laser therapy

Quality of life · children and adults with SCD and PSR

The review found no eligible studies for this question.

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs no laser therapy

Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Very low

Laser therapy vs no laser therapy

Occurence of vitreous haemorrhage · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Low

Laser therapy vs no laser therapy

Adverse effects · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Low

Colchicine (oral) vs placebo

Number of participants experiencing an attacka · people with familial Mediterranean fever

Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
RR 0.21 [0.05, 0.95]
1 study · 10 participants
Low

Rilonacept vs placebo

Prevention of AA amyloidosis · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rilonacept vs placebo

Adverse drug reactions · people with familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Rilonacept vs placebo

Acute‐phase response · people with familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

ImmunoGuard vs placebo

Number of participants experiencing an attacka · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ImmunoGuard vs placebo

Duration of attacks · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found